Kai W. Wucherpfennig
Affiliations: | Cancer Immunology and AIDS | Dana-Farber Cancer Research Institute |
Area:
T Cell Biology and Cancer ImmunologyWebsite:
http://www.fas.harvard.edu/~biophys/Kai_W_Wucherpfennig.htmGoogle:
"Kai W. Wucherpfennig"Bio:
http://www.dfhcc.harvard.edu/membership/profile/member/491/0/
http://researchers.dana-farber.org/directory/profile.asp?pict_id=0000124
http://dms.hms.harvard.edu/immunology/fac/Wucherpfennig.php
Kai W. Wucherpfennig received his M.D./Ph.D. degree from the University of Goettingen, Germany, and did postdoctoral work with Dr David Hafler at the Brigham and Women's Hospital and with Dr Jack Strominger at Harvard University before joining the faculty of the Dana-Farber Cancer Institute.
Mean distance: 17.02 | S | N | B | C | P |
Cross-listing: Chemistry Tree
Parents
Sign in to add mentor| David A. Hafler | post-doc | Brigham and Women's Hospital | |
| Jack L. Strominger | post-doc | Harvard (Chemistry Tree) |
Children
Sign in to add trainee| Matthew E. Call | grad student | 2007 | Harvard (Chemistry Tree) |
| Anne-Kathrin Wilbuer | grad student | 2011 | Harvard (Chemistry Tree) |
| Dobrin D. Draganov | grad student | 2012 | Harvard (Chemistry Tree) |
| Howell F. Moffett | grad student | 2012 | Harvard (Chemistry Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Alvarez-Calderon F, Kang BH, Kyrysyuk O, et al. (2023) Targeting of the CD161 Inhibitory Receptor Enhances T cell-mediated Immunity Against Hematological Malignancies. Blood |
| Hagel KR, Arafeh R, Gang S, et al. (2022) Systematic interrogation of tumor cell resistance to CAR T cell therapy in pancreatic cancer. Cancer Research |
| Kyrysyuk O, Wucherpfennig KW. (2022) Designing Cancer Immunotherapies That Engage T Cells and NK Cells. Annual Review of Immunology |
| Badrinath S, Dellacherie MO, Li A, et al. (2022) A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature |
| Marx S, Godicelj A, Wucherpfennig KW. (2022) A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma. Seminars in Immunopathology |
| Mathewson ND, Ashenberg O, Tirosh I, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell |
| Cartwright ANR, Suo S, Badrinath S, et al. (2021) Immunosuppressive Myeloid Cells Induce Nitric Oxide-dependent DNA Damage and p53 Pathway Activation in CD8+ T cells. Cancer Immunology Research |
| Choi IK, Wang Z, Ke Q, et al. (2020) Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature |
| Schoenfeld JD, Hanna GJ, Jo VY, et al. (2020) Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. Jama Oncology |
| Luoma AM, Suo S, Williams HL, et al. (2020) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell |